A New Phototherapy Regimen Coupled with Oral Vitamin D Supplementation, for the Long-Term Control of Atopic Dermatitis: A French Multicenter, Randomized, Crossover, Pragmatic Trial
Abstract
Introduction: The global burden of atopic dermatitis (AD) will continue to rise in the coming two decades, underscoring the need for affordable and globally accessible therapies given restricted access to high-cost medications in many regions. The study aimed to evaluate the efficacy of a novel phototherapy-based regimen as an add-on therapy, together with vitamin D supplementation, on long-term disease control in AD. Methods: The PRADA trial combined two independent randomizations within the same population: an open-label, crossover comparison of narrowband ultraviolet B (NB-UVB) phototherapy versus observation, and a double-blind, parallel-group comparison of vitamin D versus placebo, both superimposed on standard topical anti-inflammatory treatments (TAT). It was conducted between 2015 and 2023 across 16 French hospital centers. The trial included patients aged ≥ 15 years with moderate-to-severe (IGA > 2) AD and with fewer than 100 lifetime phototherapy sessions. The primary outcome was a hierarchical composite endpoint based on: (1) repeated measures of Patient-Oriented SCORing Atopic Dermatitis (PO-SCORAD) severity score over 1 year; and (2) the cumulative use of TAT from October to March. Results: A total of 53 participants were allocated to the vitamin D (26 received NB-UVB during the first period), and 57 to the placebo (27 received NB-UVB during the first period). A total of 93 participants were available for the main analysis for the primary endpoint. Vitamin D was significantly associated with lower PO-SCORAD scores compared with placebo (mean [95% CI] difference -5.6 [-12.1 to -1.78]), however, this effect size remained below the prespecified minimum clinically important difference (nine points). NB-UVB showed no significant effect on PO-SCORAD scores (mean difference: 1.25 [-3.90 to 1.40]). Adverse event incidence was 0.33 per 100 patient-months, mainly nonserious photosensitivity reactions (n = 38). Conclusions: In the PRADA trial (underpowered due to a recruitment short fall), NB-UVB phototherapy showed no clinically meaningful benefit on the long-term control of moderate-to-severe AD. The observed benefit of vitamin D supplementation on PO-SCORAD, although statistically significant, did not reach the threshold for clinical relevance. Trial registration: ClinicalTrials.gov Identifier: NCT02537509.
Related
- Orange juice and hesperidin increase flavanone exposure without detectable short-term vascular benefits: a randomized crossover trial
- Comparative efficacy and safety of systemic therapies for moderate-to-severe atopic dermatitis in adults: a systematic review of randomized controlled trials
- Long-chain Omega-3 fatty acids supplementation and cognitive performance throughout adulthood: A 6-month randomized controlled trial.
- A randomized crossover trial with weighted blankets shows improvement in behavior and sleep outcomes in adults with Prader–Willi syndrome
- Short-term effects of an SGLT2 inhibitor on divalent ions in autosomal dominant polycystic kidney disease: a randomized crossover trial
BibTeX
@article{droitcourt2026phototherapy,
title = {{A New Phototherapy Regimen Coupled with Oral Vitamin D Supplementation, for the Long-Term Control of Atopic Dermatitis: A French Multicenter, Randomized, Crossover, Pragmatic Trial}},
author = {Catherine Droitcourt and Sébastien Barbarot and Valérie Visseiche and Annabel Maruani and Monica Dinulescu and Laure Darrieux and Laurent Misery and Emilie Brenaut and Angèle Soria and Annie Vermersch and Hervé Maillard and Julien Seneschal and Alain Taieb and Cécile Chabbert and Henri Adamski and Alain Dupuy and Emmanuel Oger},
journal = {Dermatology and Therapy},
year = {2026},
month = sep,
doi = {10.1007/s13555-026-01914-8},
url = {https://u-bordeaux.hal.science/hal-05771391v1},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - A New Phototherapy Regimen Coupled with Oral Vitamin D Supplementation, for the Long-Term Control of Atopic Dermatitis: A French Multicenter, Randomized, Crossover, Pragmatic Trial
AU - Catherine Droitcourt
AU - Sébastien Barbarot
AU - Valérie Visseiche
AU - Annabel Maruani
AU - Monica Dinulescu
AU - Laure Darrieux
AU - Laurent Misery
AU - Emilie Brenaut
AU - Angèle Soria
AU - Annie Vermersch
AU - Hervé Maillard
AU - Julien Seneschal
AU - Alain Taieb
AU - Cécile Chabbert
AU - Henri Adamski
AU - Alain Dupuy
AU - Emmanuel Oger
PY - 2026
DA - 2026/09/11
JO - Dermatology and Therapy
DO - 10.1007/s13555-026-01914-8
UR - https://u-bordeaux.hal.science/hal-05771391v1
AB - Introduction: The global burden of atopic dermatitis (AD) will continue to rise in the coming two decades, underscoring the need for affordable and globally accessible therapies given restricted access to high-cost medications in many regions. The study aimed to evaluate the efficacy of a novel phototherapy-based regimen as an add-on therapy, together with vitamin D supplementation, on long-term disease control in AD. Methods: The PRADA trial combined two independent randomizations within the same population: an open-label, crossover comparison of narrowband ultraviolet B (NB-UVB) phototherapy versus observation, and a double-blind, parallel-group comparison of vitamin D versus placebo, both superimposed on standard topical anti-inflammatory treatments (TAT). It was conducted between 2015 and 2023 across 16 French hospital centers. The trial included patients aged ≥ 15 years with moderate-to-severe (IGA > 2) AD and with fewer than 100 lifetime phototherapy sessions. The primary outcome was a hierarchical composite endpoint based on: (1) repeated measures of Patient-Oriented SCORing Atopic Dermatitis (PO-SCORAD) severity score over 1 year; and (2) the cumulative use of TAT from October to March. Results: A total of 53 participants were allocated to the vitamin D (26 received NB-UVB during the first period), and 57 to the placebo (27 received NB-UVB during the first period). A total of 93 participants were available for the main analysis for the primary endpoint. Vitamin D was significantly associated with lower PO-SCORAD scores compared with placebo (mean [95% CI] difference -5.6 [-12.1 to -1.78]), however, this effect size remained below the prespecified minimum clinically important difference (nine points). NB-UVB showed no significant effect on PO-SCORAD scores (mean difference: 1.25 [-3.90 to 1.40]). Adverse event incidence was 0.33 per 100 patient-months, mainly nonserious photosensitivity reactions (n = 38). Conclusions: In the PRADA trial (underpowered due to a recruitment short fall), NB-UVB phototherapy showed no clinically meaningful benefit on the long-term control of moderate-to-severe AD. The observed benefit of vitamin D supplementation on PO-SCORAD, although statistically significant, did not reach the threshold for clinical relevance. Trial registration: ClinicalTrials.gov Identifier: NCT02537509.
SN - 2193-8210
SN - 2193-8210
ER -